Glenmark Pharmaceuticals Limited has reported strong growth in the third quarter ended December 2015, despite the challenges in certain emerging markets, from where it sees "diminishing" contribution to revenues here on.
Glenmark Hints At Emerging Markets Cutback Amid Strong Q3
Glenmark Pharmaceuticals Limited has reported strong growth in the third quarter ended December 2015, despite the challenges in certain emerging markets, from where it sees "diminishing" contribution to revenues here on.
More from Alimentary/Metabolic
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.